Also, the 5-year survival rate for patients with c-Met-positive adenocarcinomas was significantly lower than that for patients with c-Met-negative adenocarcinomas (33.9 vs 65.9%, P=0.0399, Figure 3B). The gene discussed is MET; the disease is adenocarcinoma.